Similar Papers

Paper Title
Journal
Date
Author
Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group
Grace K Dy ... Henry Tazelaar
Journal of Thoracic Oncology | VOL. 1
Grace K Dy, et. al.Grace K Dy ... Henry Tazelaar
01 Mar 2006
Characterizing platinum sensitivity among Medicare FFS patients with limited versus extensive-stage small cell lung cancer receiving NCCN category 1 preferred regimens.
Paul Cockrum ... Gabriela Dieguez
Journal of Clinical Oncology | VOL. 40
Paul Cockrum, et. al.Paul Cockrum ... Gabriela Dieguez
01 Jun 2022
116TiP KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti–PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC)
W.C.V Lai ... A Navarro
Annals of Oncology | VOL. 32
W.C.V Lai, et. al.W.C.V Lai ... A Navarro
01 Dec 2021
Thoracic radiation therapy improves the prognosis for patients with extensive stage small-cell lung cancer
Hui Zhu ...
Chinese journal of oncology | VOL. 33
Hui Zhu, et. al.Hui Zhu ...
01 Feb 2011
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
A Perspective on the MARS2 Trial
Eric Lim ... Harvey Pass
Journal of Thoracic Oncology | VOL. -
Eric Lim, et. al.Eric Lim ... Harvey Pass
01 Jan 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
Afshin Dowlati ... Saiama N Waqar
Journal of Thoracic Oncology | VOL. -
Afshin Dowlati, et. al.Afshin Dowlati ... Saiama N Waqar
01 Jan 2025
Editorial Board
-
Journal of Thoracic Oncology | VOL. -
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.